Cerus Corporation (CERS)

Currency in USD
2.720
+0.690(+33.99%)
Closed·
2.7200.000(0.00%)
·
Unusual trading volume
Trading near 52-week High
CERS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.4703.150
52 wk Range
1.1503.150
Key Statistics
Prev. Close
2.03
Open
2.69
Day's Range
2.47-3.15
52 wk Range
1.15-3.15
Volume
24.85M
Average Vol. (3m)
1.9M
1-Year Change
96.5385%
Book Value / Share
0.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CERS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.000
Upside
+83.82%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Cerus Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.000
(+83.82% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy4.00+47.06%-UpgradeMay 01, 2026
TD Cowen
Buy5.00+83.82%-MaintainJan 12, 2026
BTIG
Hold---MaintainNov 17, 2025
TD Cowen
Buy5.00+83.82%-MaintainSep 12, 2025
BTIG
Hold---MaintainAug 22, 2025

Cerus Corporation Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of -$0.01 beat forecast of -$0.05 by 80%; revenue hit $59.9M vs. $56.17M expected, up 23% YoY driven by product sales growth.
  • Gross margin declined to 52% from 58.8% YoY due to inflation and FX headwinds; adjusted EBITDA positive for eighth straight quarter at $4.0M.
  • Vivek Jayaraman appointed President and CEO; operating expenses down 7% YoY reflecting disciplined cost management and strategic focus.
  • Stock rose 5.73% after-hours to $2.03 but dipped 1.04% premarket to $1.90; shares up 45.45% over past year despite high volatility.
  • FY2026 revenue guidance set at $227M, FY2027 at $256.1M; expansion planned for INTERCEPT platform in Europe and China markets.
Last Updated: 04/30/2026, 05:24 PM
Read Full Transcript

Earnings

Latest Release
Apr 30, 2026
EPS / Forecast
-0.01 / -0.05
Revenue / Forecast
59.9M / 56.17M
EPS Revisions
Last 90 days

CERS Income Statement

Compare CERS to Peers and Sector

Metrics to compare
CERS
Peers
Sector
Relationship
P/E Ratio
−57.1x10.5x−0.5x
PEG Ratio
−1.13−0.170.00
Price / Book
8.1x2.3x2.6x
Price / LTM Sales
2.5x2.7x3.2x
Upside (Analyst Target)
83.8%56.0%48.1%
Fair Value Upside
Unlock10.3%6.6%Unlock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
65.61M34.14%178.45M
Other Institutional Investors
92.33M48.05%251.14M
Public Companies & Retail Investors
34.23M17.81%93.12M
Total
192.17M100.00%522.71M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.11.41%21,918,90359,619
ARK Investment Management LLC9.47%18,200,20449,505

People Also Watch

33.80
FLY
-2.31%
9.01
CMPS
-0.55%
22.43
TXG
+1.72%
399.04
INTU
+2.71%

FAQ

What Is the Cerus (CERS) Stock Price Today?

The Cerus stock price today is 2.720 USD.

What Stock Exchange Does Cerus Trade On?

Cerus is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cerus?

The stock symbol for Cerus is "CERS."

What Is the Cerus Market Cap?

As of today, Cerus market cap is 545.000M USD.

What Is Cerus's Earnings Per Share (TTM)?

The Cerus EPS (TTM) is -0.051.

When Is the Next Cerus Earnings Date?

Cerus will release its next earnings report on Jul 30, 2026.

From a Technical Analysis Perspective, Is CERS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cerus Stock Split?

Cerus has split 0 times.

How Many Employees Does Cerus Have?

Cerus has 268 employees.

What is the current trading status of Cerus (CERS)?

As of May 03, 2026, Cerus (CERS) is trading at a price of 2.720 USD, with a previous close of 2.030 USD. The stock has fluctuated within a day range of 2.470 USD to 3.150 USD, while its 52-week range spans from 1.150 USD to 3.150 USD.

What Is Cerus (CERS) Price Target According to Analysts?

The average 12-month price target for Cerus is 5.000 USD, with a high estimate of 5 USD and a low estimate of 5 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +83.82% Upside potential.

What Is the CERS Premarket Price?

CERS's last pre-market stock price is 2.680 USD. The pre-market share volume is 566,730.000, and the stock has decreased by 0.650, or 32.020%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.